An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
Take A Breather Foundation, a Narberth-based nonprofit, provides much-needed stress relief outlet for individuals living with ...
Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...
Parents are expressing concerns over an effort at the State House to eliminate the New Hampshire Vaccine Association, with some asking lawmakers to consider the plight of children who face significant ...
Some parents are worried about legislation moving forward at the State House that would dissolve the New Hampshire Vaccine ...
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.
Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results